|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/404 | (2006.01) |
| A61K 31/404 | (2013.01) | ||
| A61P 37/00 | (2006.01) | ||
| A61P 37/00 | (2018.01) |
| (11) | Patento numeris | 3860590 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 19790404.8 |
| Europos patento paraiškos padavimo data | 2019-10-03 | |
| (97) | Europos patento paraiškos paskelbimo data | 2021-08-11 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2023-06-07 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2019/054576 |
| Data | 2019-10-03 |
| (87) | Numeris | WO 2020/072824 |
| Data | 2020-04-09 |
| (30) | Numeris | Data | Šalis |
| 201862740855 P | 2018-10-03 | US |
| (72) |
ADAMS, John W. , US
|
| (73) |
Arena Pharmaceuticals, Inc. ,
66 Hudson Boulevard East, New York, NY 10001-2192,
US
|
| (54) | ETRASIMOD FOR USE IN METHODS FOR THE TREATMENT OF SCLERODERMA |
| ETRASIMOD FOR USE IN METHODS FOR THE TREATMENT OF SCLERODERMA |